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Neurodegenerative disorders (NDs) are characterized by abnormal accumulation/
misfolding of specific proteins, primarily α-synuclein (α-syn), β-amyloid1–42 (Aβ1–42) and
tau, in both brain and peripheral tissues. In addition to oligomers, the role of the
interactions of α-syn with Aβ or tau has gradually emerged. Nevertheless, despite
intensive research, NDs have no accepted peripheral markers for biochemical diagnosis.
In this respect, Red Blood Cells (RBCs) are emerging as a valid peripheral model for the
study of aging-related pathologies. Herein, a small cohort (N = 28) of patients affected
by Parkinson’s disease (PD) and age-matched controls were enrolled to detect the
content of α-syn (total and oligomeric), Aβ1–42 and tau (total and phosphorylated) in
RBCs. Moreover, the presence of α-syn association with tau and Aβ1–42 was explored by
co-immunoprecipitation/western blotting in the same cells, and quantitatively confirmed
by immunoenzymatic assays. For the first time, PD patients were demonstrated to
exhibit α-syn heterocomplexes with Aβ1–42 and tau in peripheral tissues; interestingly,
α-syn-Aβ1–42 concentrations were increased in PD subjects with respect to healthy
controls (HC), and directly correlated with disease severity and motor deficits. Moreover,
total-α-syn levels were decreased in PD subjects and inversely related to their motor
deficits. Finally, an increase of oligomeric-α-syn and phosphorylated-tau was observed
in RBCs of the enrolled patients. The combination of three parameters (total-α-syn,
phosphorylated-tau and α-syn-Aβ1–42 concentrations) provided the best fitting predictive
index for discriminating PD patients from controls. Nevertheless further investigations
should be required, overall, these data suggest α-syn hetero-aggregates in RBCs as a
putative tool for the diagnosis of PD.
Keywords: Parkinson’s disease, neurodegenerative disorders, α-synuclein, β-amyloid, tau, α-synuclein
heterocomplexes
Abbreviations: Aβ1–42, β-amyloid1–42; α-syn, α-synuclein; AD, Alzheimer’s disease; CSF, cerebrospinal fluid; DLB,
Dementia with Lewy Bodies; HC, healthy controls; LED, Levodopa equivalent dose; ND, Neurodegenerative disorder;
PD, Parkinson’s disease; RBCs, Red blood cells; ROC, Receiver Operating Characteristic.
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INTRODUCTION
Parkinson’s disease (PD) represents the second most common
neurodegenerative disorder (ND), with a prevalence of 1% in the
population older than 60 years (Andersen et al., 2017). To date,
no disease modifying treatment has been established, and the
continuous pathology progression results in increasing patients’
disability (Andersen et al., 2017).
The pathologic abnormalities associated with PD are primary
caused by misfolding, aggregation and brain deposition of
α-synuclein (α-syn), which constitute the major components of
Lewy bodies (LB) and Lewy neuritis (Spillantini et al., 1997;
Dickson, 2012; Miraglia et al., 2015).
Therefore, PD belongs to a group of NDs called
‘‘synucleinopathies’’, which includes dementia with Lewy
bodies (DLB) and multiple system atrophy (Irizarry et al., 1998;
Spillantini et al., 1998).
PD diagnosis is based on clinical examination (Hughes et al.,
1992) and on patients’ response to dopaminergic drugs and can
be supported by imaging techniques (Politis, 2014). Ultimate
diagnosis is achieved only post-mortem, by examining substantia
nigra damaging and the presence of LB/Lewy neuritis (Dickson,
2012; Rajput and Rajput, 2014). For these reasons, reliable
biomarkers for PD diagnosis and prognosis are urgently needed.
Although many efforts have been made in this direction, there
is still not a specific accepted biomarker for early PD diagnosis
and monitoring of disease progression (Miller and O’Callaghan,
2015).
The process of α-syn accumulation and aggregation has been
demonstrated to start even decades before the onset of clinical
disease symptoms (Compta et al., 2015; Miraglia et al., 2015)
and to reach PD cerebrospinal and peripheral fluids (Tokuda
et al., 2010). Therefore, great attempts have been devoted to
exploiting substantial biological changes and putative biomarkers
in tissue other than the brain. In this respect, cerebrospinal
fluid (CSF) has resulted the most explored fluid because it is
considered to reproduce brain pathological processes, such as
synaptic/axonal degeneration (Giacomelli et al., 2017). Several
studies have shown that in primary synucleinopathies, such
as PD and dementia with LB, CSF of patients presented
decreased levels of total α-syn and increased concentrations of its
oligomeric form (Tokuda et al., 2010; Mollenhauer et al., 2013;
Parnetti et al., 2014a,b; Compta et al., 2015; Giacomelli et al.,
2017).
Crucial disadvantages have limited the clinical diagnostic and
prognostic use of CSF biomarkers, highlighting the opportunity
to look at peripheral biomarkers that could correlate with brain
lesions and disease progression (Giacomelli et al., 2017). In this
respect, blood has emerged as a source of neurodegeneration
biomarkers because of their availability, lower cost and time
effectiveness with respect to CSF. Indeed, pathological alterations
in blood proteins have been suggested to reflect the changes
in CSF due to simple diffusion or barrier impairment that
characterizes neurodegeneration (Reiber, 2003; Giacomelli et al.,
2017). In particular, α-syn in blood is mainly contained
in red blood cells (RBCs; Barbour et al., 2008), which are
particularly sensitive to the accumulation of misfolded proteins
(Eisele et al., 2010; Pandey and Rizvi, 2010; Wang et al.,
2015). For example, recently, Papagiannakis et al. (2017) have
reported an increase of dimeric α-syn levels in erythrocyte
membranes obtained from PD patients. Other studies have
shown that the ratio oligomeric/total α-syn in RBCs is higher
in PD patients than in control subjects (Abd-Elhadi et al.,
2015; Wang et al., 2015; Zhao et al., 2016). Nevertheless,
no correlation between RBC α-syn and disease duration, age,
or motor scale score in PD patients has been evidenced
(Wang et al., 2015), thus pointing out the need of further
studies.
Actually, retrospective studies have highlighted that α-syn
level alone is not sufficient to distinguish healthy subjects
from patients with synucleinopathies or other NDs, suggesting
that other predictable biomarkers are needed (Gao et al.,
2015). In this respect, a mixed pattern of protein aggregates
in NDs has been evidenced (Baldacci et al., 2016; Giacomelli
et al., 2017). For instance, besides α-syn depositions, decreased
levels of β-amyloid1–42 (Aβ1–42) and increased microtubule-
associated protein tau concentrations have been shown to
correlate with PD cognitive decline, thus proposing Aβ1–42 and
tau as prognostic markers for cognitive deficits in PD (Sengupta
et al., 2015). Similarly, the pathophysiologic connection between
these proteins has been demonstrated in CSF of PD subjects, too
(Alves et al., 2010; Montine et al., 2010).
Interestingly, besides the ‘‘clinical overlapping’’, α-syn has
been shown to physically interact with tau (Sengupta et al.,
2015; Andersen et al., 2017) or Aβ1–42 (Parnetti et al., 2013;
Andersen et al., 2017) and to induce the formation of
hybrid oligomers (‘‘heteroaggregates’’) in PD patients’ brains.
In this context, we recently demonstrated that α-syn forms
heteroaggregates with Aβ1–42 or tau in RBCs of healthy subjects,
too (Daniele et al., 2017); in the same study, a novel home-made
immunoenzymatic assay has been employed to quantify such
oligomers, highlighting their accumulation with increasing age
and decreasing anti-oxidant capability (Daniele et al., 2017).
Herein, a cohort of PD patients and age-matched healthy
controls (HC) was enrolled to explore putative changes in α-
syn-tau and α-syn-Aβ1–42 levels between the two groups. Such
reliable measurements will be not only valuable for the discovery
of ideal blood biomarkers but also for a better understanding
of PD pathophysiological process. Moreover, α-syn (total and
oligomeric), tau (total and phosphorylated tau), and Aβ1–42
species were measured in the same subjects, in order to
investigate the usefulness of combining different biomarkers
reflecting diverse pathogenic pathways.
MATERIALS AND METHODS
Study Population and Setting of the Study
Twenty-eight patients suffering from PDwere recruited from the
Department of Neurology of the Department of Medicine of the
University of Pisa. In parallel, 45 age- and sex-matched HC were
studied (Table 1). All subjects were free of cardiovascular disease
or other major medical disorders, as assessed by clinical history
and physical examination.
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TABLE 1 | Descriptive analysis of Parkinson’s disease (PD) patients and healthy controls (HC).
PD PD de novo PD under therapy HC
N 28 14 14 45
Age (years) 67.0 ± 9.3 64.7 ± 10.6 69.4 ± 7.5 61.9 ± 7.8
Gender 12 M/16 F 4 M/10 F 8 M/6 F 18 M/27 F
UPDRS III 22.1 ± 10.3 17.7 ± 8.0 26.1 ± 10.9∗
MMSE 28.9 ± 1.8 29.3 ± 1.2 28.5 ± 2.2
H&Y 1.9 ± 0.7 1.5 ± 0.5 2.2 ± 0.7
Age of onset 64.3 ± 9.4 63.4 ± 10.9 65.1 ± 8.0
Disease duration (years) 2.8 ± 2.9
LED (mg/day) 473 ± 268
The data are the mean ± SD. Differences between groups—HC group, PD de novo subgroup, and PD under treatment subgroup—were evaluated by a non-parametric
analysis (Kruskal Wallis): ∗P < 0.05 vs. PD de novo.
All patients fulfilled the diagnostic criteria for idiopathic
PD (Hughes et al., 1992); atypical parkinsonian disorders,
such as multiple system atrophy, progressive supranuclear
palsy and corticobasal degeneration, and other neurological or
major medical conditions were considered as exclusion criteria.
Information about disease duration from symptoms onset and
therapy were collected. Fourteen patients were newly diagnosed
and drug naïve, 14 were assuming dopaminergic treatment; in
these subjects, motor assessment were performed in ON state.
Full clinical assessment was performed and the degree of motor
impairment was scored by the Hoehn and Yahr (H&Y) rating
scales (Hoehn and Yahr, 1967) and the motor (III) part of the
Unified Parkinson’s Disease Rating Scale (UPDRSIII; Fahn and
Elton, 1987). Global cognitive function was evaluated by Mini
Mental State Examination (MMSE; Folstein et al., 1975).
This study was carried out in accordance with the
recommendations of Declaration of Helsinki and Great North
West Area of Tuscany guidelines, with written informed consent
from all subjects. All subjects gave written informed consent in
accordance with the Declaration of Helsinki. The protocol was
approved by the Great NorthWest Area of Tuscany (271/2014 to
FF and 152/2016 to RC).
RBC Collection
Whole blood was collected from patients and healthy volunteers
into a tube containing EDTA as an anticoagulant. RBCs were
separated from plasma by a centrifugation at 200× g at 4◦C for
10 min (Daniele et al., 2017). The RBC pellet was centrifuged at
1000× g for 10min and washed three times with PBS. RBC pellet
was frozen at −20◦C until use. Protein content was determined
by the Bradford method. For immunoenzymatic assays, RBC
were suspended in 2 mM SDS to a final concentration of 40 mg
of total proteins in 100 µl.
Co-immunoprecipitation–Western Blotting
To confirm α-syn association with tau or Aβ1–42, a
co-immunoprecipitation assay was employed (Daniele et al.,
2017). Briefly, 1 mg of RBC lysates was resuspended in buffer
and was probed o.n. under constant rotation with an anti-α-
syn antibody (5 µg/sample), and then immunoprecipitated
with protein A-Sepharose. After extensive washing, the
immunocomplexes were resuspended in Laemmli solution,
resolved by SDS-PAGE and probed o.n. with primary antibodies
to α-syn (input), tau (H-150 SC-5587, Santa Cruz Biotechnology)
or Aβ1–42 (β-amyloid H-43 SC-9129, Santa Cruz Biotechnology).
The primary antibodies were detected using peroxidase-
conjugated secondary antibodies. The western blot experiments
were only used to investigate preliminary the presence of α -syn
heterocomplexes in RBCs of PD patients, but were not used
as quantitative data and thus not included in any statistical
analyses.
Immunoassay Methods for Total
α-Synuclein
Total α-syn was identified in RBCs following literature’s
protocols (Daniele et al., 2017). Briefly, wells were pre-coated
overnight at 4◦C with a full length antibody to α-syn (sc-
10717, Santa Cruz Biotechnology), and then bovine serum
albumin (BSA) was used to block non-specific sites for 1 h
at 37◦C (Daniele et al., 2017). RBCs (0.150 mg/100 µl) were
captured on wells for 2 h at 25◦C. Samples were then probed
with a mouse monoclonal antibody (mAb) to α-syn (Santa
Cruz, sc-12767), and subsequently with an anti-mouse-HRP
antibody. The wells were then washed four times with PBS-T
(phosphate buffered saline containing 0.01% Tween 20), the
enzyme substrate 3,3′,5,5′-tetramethylbenzidine (TMB; Thermo
Scientific) was added to the wells and the color was allowed to
develop for 30 min at room temperature. Absorbance values at
450 nm (Daniele et al., 2017).
Preparation of Aged Solutions of α-syn and
of the α-syn Biotinylated Antibody
Recombinant α-syn were incubated in tubes at 37◦C for 4 days in
an Eppendorf Thermomixer with continuousmixing (1000 rpm),
as reported previously (El-Agnaf et al., 2006; Daniele et al., 2017).
To prepare the α-syn biotinylated antibody, Sulfo-NHS-
LC-Biotin (Pierce, Rockford, IL, USA; 200 mg) was reacted
with the 211 mouse mAb (Santa Cruz Biotechnology, Santa
Cruz, CA, USA; Daniele et al., 2017). To eliminate uncoupled
biotin, the mixture was desalted on Bio-Spin-6 columns (BIO-
RAD, UK).
Detection of Oligomeric α-syn
Oligomeric α-syn levels in RBCs were measured using an
immunoenzymatic assay, as previously described (El-Agnaf et al.,
2006; Daniele et al., 2017). The plate was pre-coated overnight
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at room temperature with the mouse monoclonal α-syn
211 antibody (Santa Cruz, sc-12767). RBCs (0.04 mg/100 µl)
were added to each well for 2 h. α-syn oligomers were identified
using a specific α-syn biotinylated antibody (El-Agnaf et al.,
2006; Daniele et al., 2017). Streptavidin-horseradish peroxidase
conjugate antibody (1:1000, GE Healthcare) was used for antigen
detection. After three washes with PBS-T, 100 µl of TMB were
added in each well, as reported above.
Detection of Total Aβ1–42
Aβ1–42 levels in blood samples were measured using an immuno-
enzymatic assay, as described previously (Pesini et al., 2012;
Daniele et al., 2017). Wells were pre-coated overnight at 4◦C
with a specific antibody to Aβ1–42 (Santa Cruz, sc-9129).
After extensive washing with PBS-T, non-specific sites were
blocked with 1% BSA, and wells were incubated with RBCs
(0.2 mg/100 µl) at 25◦C for 1 h. The wells were washed with
PBS-T, and samples were probed using a specific antibody
to Aβ1–42 (sc-5399, Santa Cruz Biotechnology). The standard
curve was created using recombinant human Aβ1–42 solutions at
eight different concentrations (Pesini et al., 2012; Daniele et al.,
2017).
Detection of Total Tau
Tau levels in blood samples were measured using an immuno-
enzymatic assay, as described previously (Daniele et al., 2017).
The plate was pre-coated overnight at 4◦C with a specific
antibody to tau (Santa Cruz, sc-32274), and 1% BSA was used
to block non-specific sites. RBCs (0.5 mg/100 µl) were loaded
to each well and incubated at 25◦C for 1 h. After several
washing with PBS-T, samples were detected using a tau antibody
(sc-5587, Santa Cruz Biotechnology). The standard curve was
constructed using recombinant human tau solutions at eight
different concentrations (Daniele et al., 2017).
Immunoassay Detection of α-syn-Aβ1–42
Heterocomplexes
For the quantification of α-syn-Aβ1–42 interactions, was
used a ‘‘home-made’’ method employing a ‘‘sandwich’’
immunoenzymatic assay (Daniele et al., 2014, 2017; Zappelli
et al., 2014), as follows. Eight different dilutions of α-syn-Aβ1–42
were prepared; following capturing on wells pre-coated with a
specific antibody to Aβ1–42 (β-amyloid H-43 antibody, 1:100,
sc-9129, Santa Cruz Biotechnology; Daniele et al., 2017) in poli-
L-ornithine/NaHCO3, pH 9.6. After two washes with PBS-T,
RBCs (40 mg/sample in 2 mM SDS) were loaded to each well
and incubated at 25◦C for 2 h. One percent BSA was added for
30 min at 37◦C to block non-specific sites. To detect α-syn bound
to Aβ1–42, samples were probed for 2 h at 37◦C with a specific
antibody to α-syn (sc-12767, Santa Cruz Biotechnology), and
subsequently with the appropriate HRP-conjugated antibody.
After 1.5 h, the wells were washed twice with PBS-T, and 100 µl
of TMB were added to each well. Absorbance was measured
at 450 nm. Relative concentrations of α-syn-Aβ1–42 complexes
were calculated according to the standard curve obtained in each
microplate. The assays of blood plasma were all carried out in
duplicate. Blood samples from patients and healthy subjects were
analyzed together in batch runs. For some subjects, multiple
assays were performed on diluted RBCs from a single subject
to confirm that low or high concentrations were in the linear
range of the assay. All measurements were repeated twice and
the average value was determined (Daniele et al., 2017).
Immunoassay Detection of α-syn-tau
Heterocomplexes
For the quantification of α-syn-tau interactions, was used a
similar ‘‘home-made’’ method (see the precedent paragraph;
Daniele et al., 2017). The wells were pre-coated overnight at
room temperature with anti-α-syn antibody (1:100, sc-7012,
Santa Cruz Biotechnology) in poli-L-ornithine/NaHCO3, pH 9.6.
After two washes with PBS-T, RBCs (80 mg/sample in 2 mM
SDS) were loaded to each well and incubated at 25◦C for 2 h.
The wells were washed twice, and non-specific sites were blocked
with 1% BSA for 30 min at 37◦C. To detect α-syn bound to
tau, samples were probed for 2 h 37◦C with a specific antibody
to tau (sc-5587, Santa Cruz Biotechnology), and subsequently
with the appropriate HRP-conjugated antibody. After 1.5 h, the
wells were washed twice with PBS-T, and 100 µl of TMB were
added to each well. Absorbance wasmeasured at 450 nm. Relative
concentrations of α-syn/tau complexes were calculated according
to the standard curve obtained in each microplate (Daniele et al.,
2017).
Detection of Phosphorylated Tau
Phospho tau (p-tau) levels in blood samples were measured using
a ‘‘home-made’’ immuno-enzymatic assay (Hu et al., 2002). The
plate was pre-coated overnight at 25◦Cwith a specific antibody to
tau (Santa Cruz, sc-32274) in poli-L-ornithine/NaHCO3, pH 9.6.
After extensive washing with PBS-T, 1% BSA was used to
block non-specific sites. RBCs were loaded to each well and
incubated at 25◦C for 2 h. To detect phospho tau, samples were
probed for 1.5 h 37◦C with a specific antibody to p-tau (70R-
32555, Santa Cruz Biotechnology), and subsequently with the
appropriate HRP-conjugated antibody. After 1.5 h, the wells
were washed twice with PBS-T, and 100 µl of TMB were added
to each well. Absorbance was measured at 450 nm. Relative
concentrations of p-tau were calculated according to the standard
curve obtained in eachmicroplate. P-tau standards were obtained
from Fujirebio (Phospho-Tau Calibrator-RVC pack, Innotest
Phospho-Tau (181P)). The assays of blood plasma were all
carried out in duplicate.
Statistical Analysis
Data are presented as mean value ± SD (N = 3). The results are
expressed as ng of the measured protein/mg of the total protein
content in the RBC suspension.
The population included in this study presented a normal
distribution for age. When only two groups were present,
the non-parametric Mean-Whitney test was used (HC
subjects vs. PD patients). Differences between groups—HC
group, PD de novo subgroup, and PD under treatment
subgroup—were evaluated by a non-parametric analysis
(Kruskal Wallis). Correlation between variables was determined
by a Spearman analysis, while interactions between variables
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were calculated by correlation and multiple regression
analyses. All statistical procedures were performed using
the StatView program (Abacus Concepts, Inc., SAS Institute,
Cary, NC, USA; Franzoni et al., 2005; Daniele et al., 2017).
A receiver operating characteristic (ROC) curve was used to
calculate the relationship between sensitivity and specificity
for PD vs. HC, and the diagnostic performance of the
measured proteins in RBCs (Zhao et al., 2016). ROC analyses
were calculated using MedCalc, version 12.2.1.0 (MedCalc
Software).
RESULTS
Descriptive Analysis
Demographic and clinical data of the cohort of PD patients and
HC are reported in Table 1. The mean age of patients at sampling
was 67.0 years ± 9.3 (youngest 43, oldest 80), consisting of
12 males and 16 females. Controls (N = 45) were of 18 males and
27 females, and have a mean age of 61.9 years± 7.8 (youngest 51,
oldest 81).
PD subjects were divided into ‘‘de novo’’ when drug
naïve or ‘‘under therapy’’. Pharmacological treatments consisted
in levodopa and/or dopamine agonists (Dago), alone or in
combination with monoamine oxidase inhibitors (MAOIs). The
therapeutic regimen was expressed as levodopa equivalent dose
(LED; Tomlinson et al., 2010).
Age did not significantly differ between HC and PD patients,
or between PD de novo or under therapy. HC, PD de novo or
under therapy presented comparable sex distribution of subjects.
UPDRS III was significantly higher in PD under therapy
with respect to de novo (p = 0.0295, Table 1). The PD and
healthy subjects were recruited in parallel, and blood samples
were processed in the same way, and assayed in parallel on the
same multiwell plate for each immunoenzymatic assay.
Immunoassay Results
HC vs. PD Patients
Levels of α-syn (total and oligomeric), tau (total
and phosphorylated) and Aβ1–42 were quantified by
immunoenzymatic assays, and reported in Table 2.
The RBC concentrations of α-syn were comparable to those
previously reported from independent authors (Barbour et al.,
2008). Due to the high standard deviation of total α-syn values in
the HC population, the frequency distribution of such parameter
was analyzed (Supplementary Figure S1A). The distributions
of values led us to select a population of HC presenting
RBC α-syn concentrations of 129.46 ng/mg protein or lower
(90th percentile, Supplementary Figure S1A), on which further
comparison analyses were performed (see below).
Total α-syn in RBCs showed significant lower levels in PD
patients with respect to HC (Figure 1A, P = 0.0003). Such
difference was maintained considering the 90th percentile-HC
(P = 0.0010, Supplementary Figure S1B).
In contrast to total α-syn, an opposite trend was found for
the oligomeric form of the protein (Figure 1B, P = 0.0110).
The calculated ratio oligomeric/total α-syn resulted significantly TA
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FIGURE 1 | Immunoassay determinations in Red Blood Cells (RBCs) of Parkinson’s disease (PD) patients and healthy controls (HC). (A–E) RBC levels of total (A) and
oligomeric (B) α-synuclein (α-syn), total tau (C), p-tau (D) and Aβ1–42 (E) in the cohort of PD patients (de novo or under therapy) and HC (mean ± SD). Lysates
obtained from RBCs were subjected to specific immunoassays, as described in the “Materials and Methods” section. Differences between groups—HC group, PD
de novo subgroup, and PD under treatment subgroup—were evaluated by a non-parametric analysis (Kruskal Wallis): ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 vs. HC.
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FIGURE 2 | Correlation between total and oligomeric α-syn in RBCs. (A–D) Correlation analysis between total and oligomeric α-syn concentrations in RBCs of HC
(A), 90th percentile-HC (B), PD (C) and PD under therapy (D). Correlations were determined using a Spearman analysis. A regression line was shown for
representative purpose.
elevated in patients with respect to HC (P < 0.0001).
Furthermore, a significant positive correlation between total
and oligomeric α-syn concentrations in RBCs was found in
the total population (P = 0.0010, Rho Spearman = 0.398), as
well as in HC (HC: P = 0.0002, Rho Spearman = 0.599; 90th
percentile-HC: P = 0.0014, Rho Spearman = 0.531, Figures 2A,B)
and in the PD cohort (P = 0.0007, Rho Spearman = 0.654,
Figure 2C).
Interestingly, the levels of phosphorylated tau (p-tau,
Figure 1D, P = 0.0003) were significantly higher in the PD
cohort. Nevertheless, neither the total protein (t-tau, Figure 1C,
P = 0.5105) or the ratio p-tau/t-tau (P = 0.0713) differed between
PD subjects and HC. Similarly, total Aβ1–42 concentrations were
comparable in the two groups (Figure 1E, P = 0.2079), suggesting
that total tau and Aβ1–42 are not compromised in the analyzed
cohort of PD patients.
Finally, α-syn association with Aβ1–42 or tau were quantified
in RBCs (Figure 3 and Table 2). Recently, we have demonstrated
the presence of such heterocomplexes in human RBCs, and
validated an immunoassay for their determination (Daniele
et al., 2017). Co-immunoprecipitation analysis qualitatively
showed that α-syn associated with Aβ1–42 and tau in RBCs
from HC and PD patients (Figure 3A and Supplementary
Figure S2). Such results are consistent with those obtained in
RBCs (Daniele et al., 2017) and platelets (Daniele et al., 2018) of
HC and confirm the existence of hybrid oligomers at peripheral
level.
Quantitative immunoassays showed comparable RBC
concentrations of α-syn heterocomplexes with tau (Figure 3B,
P = 0.8738); in contrast, α-syn-Aβ1–42 heteroaggregate levels
were found to be significantly higher in PD patients with respect
to HC (Figure 3C, P = 0.0014).
HC vs. PD de novo or Under Therapy
Statistical analyses were repeated dividing PD patients in
‘‘de novo’’ (N = 14) or under therapy (N = 14).
As shown in Figure 1 and in Supplementary Figure S1,
HC presented higher levels of total α-syn with respect to
de novo (whole HC: P = 0.0150, Figure 1A; 90th percentile-
HC: P = 0.0252, Supplementary Figure S1B) or treated (whole
HC: P = 0.0015, Figure 1A; 90th percentile-HC: P = 0.0036,
Supplementary Figure S1B) patients, whereas comparable
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FIGURE 3 | α-syn heterocomplexes with tau and Aβ1–42 in RBCs. (A) Cell lysates obtained from RBCs of HC and PD patients were immunoprecipitated with an
anti-α-syn antibody, and then immunoblotted with antibody to α-syn, Aβ1–42 or tau. One representative Western blot is presented for each condition. (B,C) RBC
levels of α-syn-tau (B) or α-syn-Aβ1–42 (C) and in the cohort of PD patients (de novo or under therapy) and HC (mean ± SD). Lysates obtained from RBCs were
subjected to specific immunoassays, as described in the “Materials and Methods” section. Differences between groups—HC group, PD de novo subgroup, and PD
under treatment subgroup—were evaluated by a non-parametric analysis (Kruskal Wallis): ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 vs. HC.
concentrations were found between de novo and under therapy
subjects (P = 0.1029, Figure 1A).
Significant lower levels of oligomeric α-syn were found in
HC with respect to PD de novo only (P < 0.0001, Figure 1B).
Additionally, a slight but significant decrease in the oligomeric
protein concentrations were found in PD patients under therapy
with respect to ‘‘de novo’’ subjects (P = 0.0203, Figure 1B).
Finally, a significant positive correlation between total and
oligomeric α-syn concentrations in RBCs was evidenced in
patients under therapy (P = 0.0171, Rho Spearman = 0.662,
Figure 2D).
HC presented significant lower phosphorylated tau levels with
respect to PD de novo (P = 0.0004, Figure 1D) and under therapy
(P = 0.0363, Figure 1D). Nevertheless, the two groups of PD
patients (i.e., de novo vs. under therapy) showed comparable RBC
concentrations of p-tau (P = 0.1611, Figure 1D).
De novo and under therapy patients showed comparable
RBC concentrations of total tau (P = 0.628 Figure 1C), Aβ1–42
(P = 0.42142, Figure 1C) and α-syn/tau (P = 0.5053, Figure 3B).
In contrast, α-syn-Aβ1–42 (P = 0.0155, Figure 3C) concentrations
were found to be significantly lower in PD patients under therapy
with respect to ‘‘de novo’’ subjects. As a result, HC presented
significant lower α-syn-Aβ1–42 levels in PD de novo only (HC
vs. de novo: P = 0.0009; HC vs. under therapy: P = 0.0888,
Figure 3C). Overall, these results suggest that therapy can affect
α-syn association with Aβ1–42.
Association with Gender and Age
The RBC levels of all the measured species did not show any
association with gender in the total population, as well as in the
PD or in the HC group.
As concern age, total α-syn levels showed an inverse
correlation with age in the whole population (P = 0.0176,
Rho Spearman = −0.280, Figure 4A). Moreover, an inverse
correlation between the ratio oligomeric/total α-syn and age
(P = 0.0182, Rho Spearman = −0.196, Figure 4B) was found in
the PD cohort. Conversely, a positive correlation between total
tau and age was found in control subjects (P = 0.0497, Rho
Spearman = 0.087, Figure 4C).
Correlations with Clinical Scales in PD
Patients
An inverse correlation between total α-syn and the UPDRS
motor score was found (P = 0.0266, Rho Spearman = −0.427,
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FIGURE 4 | Correlation between RBC proteins and age. (A) Correlation analysis between age and total α-syn concentrations in RBCs of the total population.
(B) Correlation analysis between oligomeric/total α-syn concentrations of PD patients and age. (C) Correlation analysis between age and total tau concentrations in
RBCs of HC. Correlations were determined using a Spearman analysis. A regression line was shown for representative purpose.
Figure 5A) in the total PD cohort. These data are consistent with
a decrease in α-syn concentrations evidenced in PD patients with
respect to HC.
Interestingly, total tau concentrations were inversely related
to MMSE in the ‘‘de novo’’ cohort of PD patients (P = 0.0021,
Rho Spearman = −0.853, Figure 5B). These results suggest an
involvement of total tau in RBCs can be related to cognitive
decline.
Oligomeric α-syn levels in RBCs were found to be inversely
related to H&Y scale (P = 0.0051, Rho Spearman = −0.539,
Figure 5C). A similar trend was found for the UPDRS score,
although without reaching statistical significance (P = 0.0545,
Rho Spearman = −0.370). Overall, these data may suggest
oligomeric α-syn levels in RBCs decline with disease progression.
Consistent with this hypothesis, oligomeric α-syn concentrations
inversely correlated with disease duration (P = 0.0337, Rho
Spearman = −0.409, Figure 5D). However, it should be
considered that patients with a longer disease history present a
higher age and follow a therapeutic regimen (see ‘‘Discussion’’
section). In this respect, α-syn-Aβ1–42 concentrations in
RBCs correlated with the UPDRS score (P = 0.0255, Rho
Spearman = 0.620, Figure 6A), as well as with the H&Y scale
(P = 0.0161, Rho Spearman = 0.667, Figure 6B) in patients under
pharmacological treatment (see ‘‘Discussion’’ section).
Correlations with Pharmacological
Treatments
Any significant correlation with LEDs (i.e., LEDs) was evidenced
for Aβ1–42, tau and α-syn heroaggregates. Consistent with
the data depicted in Figure 1B, oligomeric α-syn content
in RBCs negatively correlated with LEDs (P = 0.0207, Rho
Spearman = −0.642, Figure 6D). Surprisingly, similar findings
were found for the total RBC levels of α-syn (P = 0.0387, Rho
Spearman =−0.334, Figure 6C).
Covariate Analysis
Covariate analysis confirmed that total tau concentrations in
RBCs are most related to the MMSE score in the total cohort of
PD patients (P = 0.0059, total P = 0.0301) and in the de novo one
(P < 0.0001, total P < 0.0001). Any other correlation was found
for the other analyzed parameters.
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FIGURE 5 | Correlation between RBC proteins and clinical scales in PD patients. (A–D) Correlation analysis between Unified Parkinson’s Disease Rating Scale
(UPDRS) motor (A), mini mental state examination (MMSE) (B), H&Y (C) scores or disease duration (D) and the levels of the indicated proteins in RBCs of PD
patients (total cohort or de novo). Correlations were determined using a Spearman analysis. A regression line was shown for representative purpose.
Receiver Operating Curve (ROC) Analysis
ROC analyses were performed to evaluate the utility of
measuring RBC concentrations of α-syn, tau and Aβ1–42 species
as a means of discriminating between PD patients and HC.
The area under the curve (AUC) provides an indication of
predictive value, with AUC = 0.5 for a random association and
AUC = 1 for perfect discrimination (Alemayehu and Zou, 2012).
A modest AUC (0.681, Figure 7A) was observed for oligomeric
α-syn (PArea0.5 = 0.0098, Table 3). Interesting results were
obtained analysis total α-syn concentrations (sensitivity = 82.14,
AUC= 0.751, PArea0.5< 0.0001, Figure 7B andTable 3) and p-tau
(AUC = 0.751, PArea0.5 < 0.0001, Figure 7C), suggesting their
potential diagnostic values. Finally, a promising predictive value
was observed for α-syn-Aβ1–42 (AUC = 0.724, PArea0.5 = 0.0007,
Figure 7D and Table 3). A combination of different biomarkers
in RBCs significantly predicts PD with an AUC of 0.982.
DISCUSSION
In the present study, the accumulation of pathological ND-linked
proteins in red blood cells of a small cohort of PD patients
was evaluated as potential marker of pathology. The main
conclusions of this work are as follows: (i) total α-syn was
demonstrated to interact with Aβ1–42 and tau in RBCs of PD
patients; (ii) α-syn-Aβ1–42 heterocomplex concentrations were
elevated in PD patients, and directly correlated with disease
severity and motor deficits in patients under therapy; (iii)
additionally, PD patients presented decreased concentrations of
total α-syn and increased levels of its oligomeric form, as well as
of phosphorylated tau; and (iv) total α-syn levels were inversely
related to motor deficits of PD patients. Finally, a combination of
different biomarkers in RBCs significantly predicts PD diagnosis
with a AUC of 0.982.
A huge amount of data has evidenced that PD hallmarks are
represented by cerebral and peripheral accumulation of α-syn,
even years or decades before the onset of clinical disease (Compta
et al., 2015; Miraglia et al., 2015). These data support the concept
that detection of accumulated/misfolded forms of abnormal
proteins in peripheral biological fluids may provide a useful tool
for an early diagnosis.
A mixed pattern of proteinopathies have been identified
in brains of patients affected by NDs (Baldacci et al.,
2016; Giacomelli et al., 2017). Moreover, in addition to
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FIGURE 6 | Correlation between RBC proteins and pharmacological treatment in PD patients. (A,B) Correlation between UPDRS motor (A) or H&Y (B) scores and
the levels of the indicated proteins in RBCs of PD patients under therapy. (C,D) Correlation analysis between the concentrations of the indicated proteins and
levodopa equivalent dose (LED). Correlations were determined using a Spearman analysis. A regression line was shown for representative purpose.
homoaggregates, α-syn, tau and Aβ have been shown to interact
each other or with other ‘‘pathological proteins’’ to form toxic
heteroaggregates in both cellular models and patients’ brain
(Parnetti et al., 2013; Sengupta et al., 2015; Andersen et al., 2017;
Giacomelli et al., 2017). These latest findings are overcoming
the concept that each neurodegenerative disease is related to the
misfolding of a single specific protein (Baldacci et al., 2016).
Herein, a cohort of de novo and under treatment patients affected
by PD was enrolled to measure α-syn, tau and Aβ1–42 species in
blood. In particular, RBCs were chosen among blood cells, based
on recent findings demonstrating an accumulation of misfolded
proteins in these cells and its relationship with NDs (Eisele et al.,
2010; Pandey and Rizvi, 2010; Kiko et al., 2012; Brown et al., 2013;
Wang et al., 2015).
In RBCs isolated from PD patients, total α-syn was
significantly lower, while the oligomeric form of the protein
and the ratio oligomeric/total α-syn resulted significantly higher.
These data are consistent with the recent findings reported in
RBCs from PD patients (Wang et al., 2015; Zhao et al., 2016;
Papagiannakis et al., 2017). Several studies have assessed the
levels of α-syn in serum or plasma of PD patients reporting
controversial findings (Atik et al., 2016). In this respect, one key
contributor to the conflicting results is that RBCs are a major
source of α-syn, accounting for more than 99% of its blood levels,
with the remainder in plasma (Barbour et al., 2008).
Total α-syn levels showed an inverse correlation with age in
the whole population. Furthermore, consistent with its decreased
levels in patients, an inverse correlation between total α-syn
and the UPDRS motor score was found in the total PD cohort.
Otherwise, in a previous article, no correlation between RBC
α-syn oligomer levels and age at onset, disease duration, age,
UPDRS motor scale score or progression of motor degeneration
in PD patients (Wang et al., 2015) was observed.
We found that oligomeric α-syn levels in RBCs were inversely
related to disease severity (i.e., H&Y score), thus suggesting that
the oligomeric protein levels in RBCs may decline along with
disease progression. In contrast, two independent studies have
shown that CSF oligomeric α-syn levels increase in advanced
PD patients with dementia (Compta et al., 2015). However, in
interpreting our results, it should be considered that patients with
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FIGURE 7 | (A–D) Receiver Operating Characteristic (ROC) curves to evaluate
the utility of RBC concentrations of oligomeric α-syn (A), total α-syn (B), p-tau
(C) or α-syn-Aβ1–42 (D) in discriminating PD patients from HC.
a longer disease history generally present a higher age and follow
a therapeutic regimen. In this respect, subjects under therapy
presented significant lower RBC concentrations of oligomeric
α-syn with respect to de novo patients. Moreover, oligomeric
α-syn levels showed an inverse correlation with LEDs, thus
supporting the hypothesis that drugs can affect the content of
the protein. In this respect, dopaminergic agonists and MAO
inhibitors have been demonstrated to reduce α-syn aggregation
both in vitro (Ono et al., 2007) and in a Drosophila model of
synucleinopathy (Yedlapudi et al., 2016). On the other hand,
Levodopa administration, in particular in long-time therapies,
can lead to increased oxidative stress and inflammatory response
of PD patients (Dorszewska et al., 2014) even in peripheral blood
cells (Dorszewska and Kozubski, 2011), possibly influencing
protein accumulation in RBCs, which are particularly sensitive
to oxidative stress (Pandey and Rizvi, 2011). Similarly, the MAO
blocker selegiline, contrary to rasagiline, has been shown to
induce a more compact α-syn structure (Kakish et al., 2015).
Therefore, the different contributions of medical treatment on
α-syn accumulation/aggregation in RBCs should be considered.
Further experiments on a larger cohort of PD patients under
therapy are ongoing in order to dissect the contribution
of Levodopa, dopaminergic agonists or MAO inhibitors on
synuclein misfolding.
PD patients showed an enhancement in the phosphorylated,
but not total, levels of tau with respect to HC, thus supporting
the hypothesis of a tau involvement in PD pathogenesis.
Consistent with our data, histopathological studies have detected
phosphorylated tau in neurofibrillary tangles, LB and neurites
of PD and DLB cases (Arima et al., 2000; Ishizawa et al.,
2003), where it colocalizes with α-syn. Conversely, decreased
levels of total and/or phoshorylated tau have been found in
CSF or in plasma (Sparks et al., 2012) of subjects with PD,
Alzheimer’s disease (AD) and MCI compared to cognitively
normal controls, with a significant positive correlation between
changing levels of plasma tau and cognitive performance (Sparks
et al., 2012). Besides the different NDs, such discrepancy
may be due to the different blood fluid analyzed in the
studies, and highlights that further investigations are needed
to clarify the benefits of blood tau as a biomarker in PD and
other NDs.
A positive correlation between total tau and age was
found in control and in PD subjects, although without
statistical significance in the latter cohort. Interestingly,
total tau concentrations were directly related to cognitive
deficits in PD patients in the ‘‘de novo’’ cohort. These
results suggest an involvement of total tau in RBCs can be
related to cognitive decline. Consistent with our data, tau
aggregation/phosphorylation have been shown to increase
in PD dementia (PDD) with respect to PD (Compta et al.,
2009; Hall et al., 2012) and to correlate with cognitive status
(Jellinger, 2007). Nevertheless, it should be noticed that our
cohort of PD patients presented quite normal cognitive state.
To overcome such limitation, the contribute of total and
phosphorylated tau in PD with dementia will be explored in a
future study.
Total levels of Aβ1–42 in RBCs did not differ between PD
and HC. Consistent with our findings, the protein levels in CSF
have been demonstrated not to differ in PD compared with
controls (Mollenhauer et al., 2011). However, studies on Aβ1–42
contribution in PD are still in progress. Considering the striking
role of Aβ1–42 in PD conversion to dementia (Compta et al.,
2013; Alves et al., 2014) and its accumulation with age in RBCs
(Kiko et al., 2012), an interesting development of our study will
be to assess Aβ1–42 levels in PD patients with marked cognitive
deficits.
Interestingly, in this study it was demonstrated for the
first time that PD patients exhibited α-syn heterocomplexes
with Aβ1–42 and tau in peripheral tissues too, as demonstrated
TABLE 3 | Parameters of ROC analyses for RBC levels of total α-syn, oligomeric α-syn, α-syn-Aβ1–42 and p-tau.
ROC parameters Total α-syn Oligomeric α-syn α-syn-Aβ1–42 p-tau
AUC 0.751 0.681 0.724 0.751
PArea0.5 P < 0.0001 P = 0.0098 P = 0.0007 P < 0.0001
Sensitivity (%) 82.14 56.57 64.29 57.14
Specificity (%) 66.67 87.80 75.56 87.67
PArea0.5 indicates the statistical significance for Area = 0.5.
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previously in patients’ brains (Parnetti et al., 2013; Sengupta
et al., 2015; Andersen et al., 2017). By the mean of a validated
immunoenzymatic assay, the levels of α-syn heterocomplexes
were quantified: HC presented comparable RBC concentrations
of α-syn-tau with respect to PD subjects, while a highly
significant enhancement of α-syn-Aβ1–42 species was found in
pathological RBCs. No correlation with disease duration or
severity was found in the total PD cohort, probably due to the
small number of subjects. Nevertheless, a promising predictive
value was observed for α-syn-Aβ1–42, with an AUC of 0.714.
Interestingly, α-syn-Aβ1–42 concentrations were significantly
lower in PD patients under therapy with respect to ‘‘de novo’’.
It is possible that the effect of disease on α-syn-Aβ1–42
concentrations is overcome by the effect of age (the values
decrease with age), whereas as a mere disease effect, in the cohort
under pharmacological treatment, α-syn-Aβ1–42 concentrations
in RBCs would increase with worse motor deficits and disease
severity.
Herein, α-syn was demonstrated to interact with Aβ1–42
and tau in RBCs of PD patients; in particular, α-syn-
Aβ1–42 concentrations were elevated in PD subjects and
directly correlated with disease severity and motor deficits in
patients under therapy. Moreover, PD was confirmed to be
associated with decreased concentrations of total α-syn, which
inversely related to motor deficits of patients. Furthermore,
an enhancement of oligomeric α-syn, total and phosphorylated
tau was observed, with a direct correlation between total tau
concentrations and cognitive impairment.
Some limitations have to be considered in this study:
the small cohort of subjects and the unavailability of CSF
samples from patients, which would be necessary to correlate
exactly RBCs-CSF data. Further studies on larger cohort
of pathologically confirmed subjects will overcome these
limitations, shedding light on the real sensitivity and specificity
of α-syn heterocomplexes in RBCs.
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